Combination bromo- and extraterminal domain and poly (ADP-ribose) polymerase inhibition synergistically enhances DNA damage and inhibits neuroblastoma tumorigenesis

Abstract Purpose JQ1 is a bromo- and extraterminal (BET) domain inhibitor that downregulates MYC expression and impairs the DNA damage response. Poly (ADP-ribose) polymerase (PARP) inhibitors prevent DNA damage sensing and repair. We hypothesized that JQ1 would promote a DNA repair-deficient phenoty...

Full description

Bibliographic Details
Main Authors: Jillian C. Jacobson, Jingbo Qiao, Rachael A. Clark, Dai H. Chung
Format: Article
Language:English
Published: Springer 2022-10-01
Series:Discover Oncology
Subjects:
Online Access:https://doi.org/10.1007/s12672-022-00563-5
_version_ 1817985355453825024
author Jillian C. Jacobson
Jingbo Qiao
Rachael A. Clark
Dai H. Chung
author_facet Jillian C. Jacobson
Jingbo Qiao
Rachael A. Clark
Dai H. Chung
author_sort Jillian C. Jacobson
collection DOAJ
description Abstract Purpose JQ1 is a bromo- and extraterminal (BET) domain inhibitor that downregulates MYC expression and impairs the DNA damage response. Poly (ADP-ribose) polymerase (PARP) inhibitors prevent DNA damage sensing and repair. We hypothesized that JQ1 would promote a DNA repair-deficient phenotype that sensitizes neuroblastoma cells to PARP inhibition. Methods Four human neuroblastoma cell lines were examined: two MYCN-amplified (BE(2)-C and IMR-32), and two non-MYCN-amplified (SK-N-SH and SH-SY5Y). Cells were treated with JQ1 (BET inhibitor), Olaparib (PARP inhibitor), or in combination to assess for therapeutic synergy of JQ1 and Olaparib. Treated cells were harvested and analyzed. Quantitative assessment of combination treatment synergy was performed using the median effect principle of Chou and Talalay. Results Combination treatment with Olaparib decreased the IC50 of JQ1 by 19.9-fold, 2.0-fold, 12.1-fold, and 2.0-fold in the BE(2)-C, IMR-32, SK-N-SH, and SH-SY5Y cell lines, respectively. In the MYCN-amplified cell lines, BE(2)-C and IMR-32, combination treatment decreased gene expression of MYCN relative to single-drug treatment alone or control. Combination treatment decreased protein expression of DNA repair proteins Ku80 and RAD51, led to accumulation of DNA damage marker phospho-histone H2A.X, and increased caspase activity. In the non-MYCN-amplified cell lines, SK-N-SH and SH-SY5Y, combination treatment induced G0/G1 cell cycle arrest. Conclusions Combination BET and PARP inhibition synergistically inhibited neuroblastoma tumorigenesis in vitro. In MYCN-amplified neuroblastoma cells, this effect may be induced by downregulation of MYCN transcription, defects in DNA repair, accumulation of DNA damage, and apoptosis. In non-MYCN-amplified cell lines, combination treatment induced cell cycle arrest.
first_indexed 2024-04-13T23:57:03Z
format Article
id doaj.art-f4a3c8118f6d43999eb0fc72ab4b40dc
institution Directory Open Access Journal
issn 2730-6011
language English
last_indexed 2024-04-13T23:57:03Z
publishDate 2022-10-01
publisher Springer
record_format Article
series Discover Oncology
spelling doaj.art-f4a3c8118f6d43999eb0fc72ab4b40dc2022-12-22T02:23:51ZengSpringerDiscover Oncology2730-60112022-10-0113112010.1007/s12672-022-00563-5Combination bromo- and extraterminal domain and poly (ADP-ribose) polymerase inhibition synergistically enhances DNA damage and inhibits neuroblastoma tumorigenesisJillian C. Jacobson0Jingbo Qiao1Rachael A. Clark2Dai H. Chung3Department of Pediatric Surgery, University of Texas Southwestern Medical Center and Children’s HealthDepartment of Pediatric Surgery, University of Texas Southwestern Medical Center and Children’s HealthDepartment of Pediatric Surgery, University of Texas Southwestern Medical Center and Children’s HealthDepartment of Pediatric Surgery, University of Texas Southwestern Medical Center and Children’s HealthAbstract Purpose JQ1 is a bromo- and extraterminal (BET) domain inhibitor that downregulates MYC expression and impairs the DNA damage response. Poly (ADP-ribose) polymerase (PARP) inhibitors prevent DNA damage sensing and repair. We hypothesized that JQ1 would promote a DNA repair-deficient phenotype that sensitizes neuroblastoma cells to PARP inhibition. Methods Four human neuroblastoma cell lines were examined: two MYCN-amplified (BE(2)-C and IMR-32), and two non-MYCN-amplified (SK-N-SH and SH-SY5Y). Cells were treated with JQ1 (BET inhibitor), Olaparib (PARP inhibitor), or in combination to assess for therapeutic synergy of JQ1 and Olaparib. Treated cells were harvested and analyzed. Quantitative assessment of combination treatment synergy was performed using the median effect principle of Chou and Talalay. Results Combination treatment with Olaparib decreased the IC50 of JQ1 by 19.9-fold, 2.0-fold, 12.1-fold, and 2.0-fold in the BE(2)-C, IMR-32, SK-N-SH, and SH-SY5Y cell lines, respectively. In the MYCN-amplified cell lines, BE(2)-C and IMR-32, combination treatment decreased gene expression of MYCN relative to single-drug treatment alone or control. Combination treatment decreased protein expression of DNA repair proteins Ku80 and RAD51, led to accumulation of DNA damage marker phospho-histone H2A.X, and increased caspase activity. In the non-MYCN-amplified cell lines, SK-N-SH and SH-SY5Y, combination treatment induced G0/G1 cell cycle arrest. Conclusions Combination BET and PARP inhibition synergistically inhibited neuroblastoma tumorigenesis in vitro. In MYCN-amplified neuroblastoma cells, this effect may be induced by downregulation of MYCN transcription, defects in DNA repair, accumulation of DNA damage, and apoptosis. In non-MYCN-amplified cell lines, combination treatment induced cell cycle arrest.https://doi.org/10.1007/s12672-022-00563-5NeuroblastomaBETPARPJQ1Olaparib
spellingShingle Jillian C. Jacobson
Jingbo Qiao
Rachael A. Clark
Dai H. Chung
Combination bromo- and extraterminal domain and poly (ADP-ribose) polymerase inhibition synergistically enhances DNA damage and inhibits neuroblastoma tumorigenesis
Discover Oncology
Neuroblastoma
BET
PARP
JQ1
Olaparib
title Combination bromo- and extraterminal domain and poly (ADP-ribose) polymerase inhibition synergistically enhances DNA damage and inhibits neuroblastoma tumorigenesis
title_full Combination bromo- and extraterminal domain and poly (ADP-ribose) polymerase inhibition synergistically enhances DNA damage and inhibits neuroblastoma tumorigenesis
title_fullStr Combination bromo- and extraterminal domain and poly (ADP-ribose) polymerase inhibition synergistically enhances DNA damage and inhibits neuroblastoma tumorigenesis
title_full_unstemmed Combination bromo- and extraterminal domain and poly (ADP-ribose) polymerase inhibition synergistically enhances DNA damage and inhibits neuroblastoma tumorigenesis
title_short Combination bromo- and extraterminal domain and poly (ADP-ribose) polymerase inhibition synergistically enhances DNA damage and inhibits neuroblastoma tumorigenesis
title_sort combination bromo and extraterminal domain and poly adp ribose polymerase inhibition synergistically enhances dna damage and inhibits neuroblastoma tumorigenesis
topic Neuroblastoma
BET
PARP
JQ1
Olaparib
url https://doi.org/10.1007/s12672-022-00563-5
work_keys_str_mv AT jilliancjacobson combinationbromoandextraterminaldomainandpolyadpribosepolymeraseinhibitionsynergisticallyenhancesdnadamageandinhibitsneuroblastomatumorigenesis
AT jingboqiao combinationbromoandextraterminaldomainandpolyadpribosepolymeraseinhibitionsynergisticallyenhancesdnadamageandinhibitsneuroblastomatumorigenesis
AT rachaelaclark combinationbromoandextraterminaldomainandpolyadpribosepolymeraseinhibitionsynergisticallyenhancesdnadamageandinhibitsneuroblastomatumorigenesis
AT daihchung combinationbromoandextraterminaldomainandpolyadpribosepolymeraseinhibitionsynergisticallyenhancesdnadamageandinhibitsneuroblastomatumorigenesis